DJS Antibodies Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 18

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $287M

DJS Antibodies General Information

Description

Developer of novel therapeutic monoclonal antibodies designed to target G-protein-coupled receptors (GPCRs). The company specializes in the research and discovery of functional antibodies to complex protein targets that have been intractable to drug discovery in order to isolate high-quality antibodies against proteins, enabling physicians to treat currently undruggable and untreatable diseases.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • Cherwell Innovation Centre
  • 77 Heyford Park, Upper Heyford, Oxfordshire
  • Bicester OX25 5HD
  • England, United Kingdom
+44 01865
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
Vertical(s)
Corporate Office
  • Cherwell Innovation Centre
  • 77 Heyford Park, Upper Heyford, Oxfordshire
  • Bicester OX25 5HD
  • England, United Kingdom
+44 01865

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

DJS Antibodies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Merger/Acquisition 19-Oct-2022 $287M Completed Generating Revenue
10. Seed Round 02-Feb-2022 Completed Generating Revenue
9. Seed Round 22-Dec-2020 Completed Generating Revenue
8. Grant 01-Jun-2020 Completed Pre-Clinical Trials
7. Grant 01-Apr-2019 Completed Pre-Clinical Trials
6. Grant 01-Dec-2017 Completed Pre-Clinical Trials
5. Seed Round 05-Oct-2016 Completed Pre-Clinical Trials
4. Accelerator/Incubator 04-Apr-2016 Completed Pre-Clinical Trials
3. Accelerator/Incubator 01-Jan-2016 Completed Pre-Clinical Trials
2. Grant 01-Nov-2015 $38.3K Completed Pre-Clinical Trials
To view DJS Antibodies’s complete valuation and funding history, request access »

DJS Antibodies Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Preference Shares
Ordinary 1
To view DJS Antibodies’s complete cap table history, request access »

DJS Antibodies Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of novel therapeutic monoclonal antibodies designed to target G-protein-coupled receptors (GPCRs). The company
Drug Discovery
Bicester, United Kingdom
18 As of 2025

Redcar, United Kingdom
 

Vannas, Sweden
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

DJS Antibodies Competitors (11)

One of DJS Antibodies’s 11 competitors is Absolute Antibody, a Private Equity-Backed company based in Redcar, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Absolute Antibody Private Equity-Backed Redcar, United Kingdom
Agrisera Formerly PE-Backed Vannas, Sweden
Crescendo Biologics Venture Capital-Backed Cambridge, United Kingdom
Integrated DNA Technologies Formerly PE-Backed Coralville, IA
Personal Genome Diagnostics Formerly VC-backed Baltimore, MD
You’re viewing 5 of 11 competitors. Get the full list »

DJS Antibodies Patents

DJS Antibodies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-12599645-B2 Antibodies which bind to lysophosphatidic acid receptor 1 (lpar1) Active 02-Sep-2021
US-20260294999-A1 Antibodies which bind to lysophosphatidic acid receptor 1 (lpar1) Pending 02-Sep-2021
AU-2022338282-A1 Polypeptides Pending 02-Sep-2021
AU-2026226436-A1 Polypeptides Pending 02-Sep-2021
CA-3230808-A1 Polypeptides Pending 02-Sep-2021 C07K14/705
To view DJS Antibodies’s complete patent history, request access »

DJS Antibodies Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

DJS Antibodies Former Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Amgen Ventures Corporate Venture Capital Minority
Innovate UK Government
Johnson & Johnson JJDC Corporate Venture Capital Minority
LifeArc Ventures Venture Capital Minority
MassChallenge Accelerator/Incubator Minority
You’re viewing 5 of 9 investors. Get the full list »

DJS Antibodies FAQs

  • When was DJS Antibodies founded?

    DJS Antibodies was founded in 2014.

  • Where is DJS Antibodies headquartered?

    DJS Antibodies is headquartered in Bicester, United Kingdom.

  • What is the size of DJS Antibodies?

    DJS Antibodies has 18 total employees.

  • What industry is DJS Antibodies in?

    DJS Antibodies’s primary industry is Drug Discovery.

  • Is DJS Antibodies a private or public company?

    DJS Antibodies is a Private company.

  • What is the current valuation of DJS Antibodies?

    The current valuation of DJS Antibodies is .

  • What is DJS Antibodies’s current revenue?

    The current revenue for DJS Antibodies is .

  • How much funding has DJS Antibodies raised over time?

    DJS Antibodies has raised $17.5M.

  • Who are DJS Antibodies’s investors?

    Amgen Ventures, Innovate UK, Johnson & Johnson JJDC, LifeArc Ventures, and MassChallenge are 5 of 9 investors who have invested in DJS Antibodies.

  • Who are DJS Antibodies’s competitors?

    Absolute Antibody, Agrisera, Crescendo Biologics, Integrated DNA Technologies, and Personal Genome Diagnostics are some of the 11 competitors of DJS Antibodies.

  • When was DJS Antibodies acquired?

    DJS Antibodies was acquired on 19-Oct-2022.

  • Who acquired DJS Antibodies?

    DJS Antibodies was acquired by AbbVie.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process